Part 1
Drug Legalization Series Part 1: Drug Legalization Isn’t Endorsement. It’s Regulation and Harm Reduction.
Drug legalization isn’t endorsement. Part 1 explains why punishment fails, why reentry is deadly, and why harm reduction saves lives.
Drug Legalization Series
Drug Legalization Series
A multi-part essay series on drug legalization, regulation, harm reduction, reentry, and public health — written from lived experience and grounded in evidence.
This series argues that drug policy should be written for outcomes — not fear, stigma, or moral panic. Each part builds on the last: from why punishment fails, to what regulation actually looks like, to pilot programs, case studies, and the reentry window we keep wasting.
New to the series? Start with Part 1: Drug Legalization Isn’t Endorsement. For the policy blueprint, read Part 1.5. Programs working in recovery and reentry may also want ReturnPath — the facilitator-led curriculum behind this work.
All posts Reentry & Policy Recovery Topics
-
-
Part 1.5
Drug Legalization Series Part 1.5: Legalization vs Decriminalization vs Regulation: Drug Policy Explained
Legalization isn’t one policy. This post explains legalization vs decriminalization vs regulation, and what strict regulation actually delivers in safety and outcomes.
-
Part 2
Drug Legalization Series Part 2: How Drug Criminalization Creates a Permanent Underclass
Drug felony consequences go far beyond court. Here’s how felony drug possession consequences create employment and housing barriers, crush credit, and trap people long after release.
-
Part 3
Drug Legalization Series Part 3: The Hidden Sentence
Being convicted of a drug felony: voting rights, gun rights, and the permanent sentence that is rarely talked about. Part 3 in the drug legalization series.
-
Part 4
Drug Legalization Series Part 4: What Drug Legalization and Regulation Actually Buys Us
Drug legalization and regulation is not endorsement. It is a regulated drug supply with testing, labeling, fentanyl test strips, and real accountability that prohibition cannot deliver.
-
Part 5
Drug Legalization Series Part 5: How Illegal Drug Markets Power Gangs and Cartels
Drug prohibition violence is not an accident. It is a predictable result of illegal markets. How gangs and drug trafficking, cartel revenue, and drug market violence grow under prohibition.
-
Part 6
Drug Legalization Series Part 6: Tusi (Pink Cocaine), Xylazine, and THC Analogues: Why Enforcement Can’t Keep Up
Tusi (pink cocaine), xylazine, medetomidine, nitazenes, and THC analogues prove enforcement can’t keep up. Regulation creates testing, labeling, and accountability.
-
Part 7
Drug Legalization Series Part 7: Recovery Lockbox: Fund Addiction Treatment Without Raising Taxes
A recovery lockbox captures enforcement savings and regulated-market revenue to fund MOUD, recovery housing, and reentry using National Drug Control Budget FY 2025 realities and real jail costs.
-
Part 8
Drug Legalization Series Part 8: Fear Is Not a Policy: The Known Failure vs the Imagined Risk
In part 8 of the drug legalization blog series, we explore fear-based drug policy, Oregon's Measure 110 results, and what effective policy would entail.
-
Part 9
Drug Legalization Series Part 9: What Regulation Would Actually Look Like
This post explains what risk-based drug regulation looks like in practice: a risk-tier model built around supply control, age limits, potency limits, licensing, taxation, enforcement priorities, and the recovery infrastructure required to make it real.
-
Part 10
Drug Legalization Series Part 10: With Drug Legalization, Accountability Still Exists
In part 10 of the drug legalization and regulation series, we explore how drug legalization accountability answers a hard question: what gets enforced when use isn’t a crime, and how a regulated drug market protects the public.
-
Part 11
Drug Legalization Series Part 11: Prevention That Isn’t Propaganda
Evidence-based drug prevention programs beat scare tactics—here’s what actually reduces youth drug use, why fear-based drug education fails, and how prevention fits inside drug legalization and strict regulation.
-
Part 12
Drug Legalization Series Part 12: The Reentry Window We Keep Wasting
Prison release overdose risk is highest in the first days and weeks after release. This chapter explains which pre-release and post-release programs actually reduce overdose, recidivism, and instability.
-
Part 13
Drug Legalization Series Part 13: Mental Health, Housing, and Despair
We explore the connection between drug addiction and homelessness, mental illness, and housing first addiction recovery in part 13 of the drug legalization and regulation series.
-
Part 14
Drug Legalization Series Part 14: A Regulated Pharmacy Model for High-Risk Substances
A regulated pharmacy model for high-risk substances could replace street chaos with standards, cut overdose risk, and connect people to treatment on demand fast.
-
Part 15
Drug Legalization Series Part 15: Arguments Against Drug Legalization: The Hard Objections, Answered Directly
The strongest arguments against drug legalization deserve direct answers. This post breaks down drug legalization pros and cons, youth access, public safety, mental health, and whether legalization actually increases drug use.
-
Part 16
Drug Legalization Series Part 16: How to Run a Drug Legalization Pilot Program Without Betting the Farm
Part 16 lays out a drug legalization pilot program framework that pilots risk-based drug regulation, measures overdose prevention and public safety outcomes, and scales only what works with strong diversion control, 42 CFR Part 2 privacy, and outcomes-based funding.
-
Part 17
Drug Legalization Series Part 17: Case Studies Without Cherry-Picking
Part 17 uses real drug policy case studies to examine what worked, what failed, and why across Portugal drug decriminalization, Oregon Measure 110 results, British Columbia safer supply, Switzerland heroin-assisted treatment, and cannabis legalization outcomes.
-
Part 18
Drug Legalization Series Part 18: Ditching Moral Panic For A Public Health Approach
Part 18 makes the case for a public health approach to drug policy over moral panic, using harm reduction strategies, overdose prevention, addiction stigma reduction, and risk-based drug regulation to reduce death, disorder, and failed policy.
-
Part 19
Drug Legalization Series Part 19: The Myth That Regulation Is Too Complex to Run
Part 19 explains why controlled substance regulation is already being administered every day through prescription drug monitoring program systems, methadone clinic regulations, buprenorphine prescribing rules, pharmacy oversight, and the regulated pharmacy model logic behind risk-based reform.